LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Prognostic Impact of Adiposity in Hematological Malignancies: A Systematic Review and Meta-analysis.

    Aleixo, Gabriel F P / Sheu, Michael / Mirzai, Saeid / Majhail, Navneet S

    Clinical lymphoma, myeloma & leukemia

    2022  Volume 22, Issue 10, Page(s) 726–734

    Abstract: It has been proposed that direct measurement of adiposity has a greater accuracy as a prognostic factor in various malignancies than anthropometric measures such as BMI. We evaluated the association of visceral and subcutaneous adiposity with outcomes in ...

    Abstract It has been proposed that direct measurement of adiposity has a greater accuracy as a prognostic factor in various malignancies than anthropometric measures such as BMI. We evaluated the association of visceral and subcutaneous adiposity with outcomes in patients with hematological malignancies with a systematic review and meta-analysis. This systematic review included patients with hematological malignancies who had the analysis of overall mortality and progression-free survival according to their adiposity status. We identified 3137 articles, of which we included seven studies. Patients with visceral low visceral adiposity had 2 times greater mortality risk (HR 2.02, P = .0004) and 80% higher risk of death or disease progression (HR 2.98, P = 0.0002), than patients with normal visceral obesity. Patients classified with subcutaneous adipopenia had almost 3 times greater mortality risk. In conclusion, hematological malignancy patients having low adiposity (subcutaneous or visceral) have worse outcomes.
    MeSH term(s) Adiposity ; Body Mass Index ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/pathology ; Humans ; Intra-Abdominal Fat/pathology ; Obesity/complications ; Prognosis
    Language English
    Publishing date 2022-05-29
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Review ; Systematic Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2022.05.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies.

    Mian, Agrima / Bhattarai, Narendra / Sheu, Michael / Ondrejka, Sarah L / Caimi, Paolo F / Hill, Brian T

    British journal of haematology

    2022  Volume 198, Issue 5, Page(s) e71–e74

    MeSH term(s) Antigens, CD19 ; Humans ; Lymphoma, B-Cell/pathology ; Lymphoma, Non-Hodgkin/pathology ; Neoplasm Recurrence, Local/drug therapy
    Chemical Substances Antigens, CD19
    Language English
    Publishing date 2022-06-22
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18333
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Late complications after allogeneic hematopoietic cell transplant: What primary care physicians can do.

    Granat, Lauren M / Ondeck, Mariah / Osantowski, Bennett / Sheu, Michael / Ganesan, Vishwanath / Rotz, Seth / Hamilton, Betty K

    Cleveland Clinic journal of medicine

    2023  Volume 90, Issue 8, Page(s) 499–508

    Abstract: Survivors of allogeneic hematopoietic cell transplant (HCT) face the risk of many serious complications in the long term, which primary care physicians play an integral role in recognizing and treating. In this review, the authors summarize the most ... ...

    Abstract Survivors of allogeneic hematopoietic cell transplant (HCT) face the risk of many serious complications in the long term, which primary care physicians play an integral role in recognizing and treating. In this review, the authors summarize the most common complications that primary care physicians see after HCT recipients return to their care: chronic graft-vs-host disease; cardiovascular, metabolic, endocrine, rheumatologic, orthopedic, infectious, neurologic, and cognitive complications; secondary malignancies; psychiatric disorders; and impairments in quality of life and sexual health. Also discussed are health maintenance and screening recommendations for this patient population.
    MeSH term(s) Humans ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation/adverse effects ; Quality of Life ; Physicians, Primary Care ; Bronchiolitis Obliterans Syndrome
    Language English
    Publishing date 2023-08-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 639116-3
    ISSN 1939-2869 ; 0891-1150
    ISSN (online) 1939-2869
    ISSN 0891-1150
    DOI 10.3949/ccjm.90a.23006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection-related hospitalizations in multiple myeloma patients.

    Sheu, Michael / Molina Garcia, Sofia / Patel, Meera / Granat, Lauren / Williams, Louis / Khouri, Jack / Mossad, Sherif / Anwer, Faiz / Majeed, Aneela

    Hematological oncology

    2023  Volume 41, Issue 4, Page(s) 718–724

    Abstract: This study explored the efficacy of intravenous immunoglobulin (IVIG) prophylaxis in reducing infection-related hospitalizations (IRHs) in MM patients. This was a retrospective study of MM patients who received IVIG at Taussig Cancer Center between July ... ...

    Abstract This study explored the efficacy of intravenous immunoglobulin (IVIG) prophylaxis in reducing infection-related hospitalizations (IRHs) in MM patients. This was a retrospective study of MM patients who received IVIG at Taussig Cancer Center between July 2009 and July 2021. The primary endpoint was rate of IRHs per patient-year on-IVIG versus off-IVIG. 108 patients were included. There was a significant difference in the primary endpoint of rate of IRHs per patient-year on-IVIG versus off-IVIG in the overall study population (0.81 vs. 1.08; Mean Difference [MD], -0.27; 95% Confidence Interval [CI], -0.57 to 0.03; p value [P] = 0.04). The subgroup of patients with a 1-year period of continuous IVIG (49, 45.3%), the subgroup with standard-risk cytogenetics (54, 50.0%) and the subgroup with 2 or more IRHs (67, 62.0%) all showed a significant reduction in IRHs while on-IVIG versus off-IVIG (0.48 vs. 0.78; MD, -0.30; 95% CI, -0.59 to 0.002; p = 0.03) and (0.65 vs. 1.01; MD, -0.36; 95% CI, -0.71 to -0.01; p = 0.02) and (1.04 vs. 1.43; MD, -0.39; 95% CI, -0.82 to 0.05; p = 0.04) respectively. IVIG showed significant benefit in reducing IRHs in the overall population and in multiple subgroups.
    MeSH term(s) Humans ; Immunoglobulins, Intravenous/therapeutic use ; Multiple Myeloma/drug therapy ; Retrospective Studies ; Hospitalization
    Chemical Substances Immunoglobulins, Intravenous
    Language English
    Publishing date 2023-05-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3185
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top